Kyverna Therapeutics appoints cell therapy veteran Mert Aktar to board

Kyverna Therapeutics, Inc.

Appointed Mert Aktar as Class III director, effective Oct 20, 2024; joins Audit and Science & Technology Committees.
Aktar currently CEO of Receptive Bio; previously SVP Global Head of Corp Dev at Kite Pharma; over 20 years biopharma experience.
As non-employee director, receives $40k/yr cash, $10k Audit, $7.5k SciTech committee fees; plus $350k option grant vesting monthly over 3 years.
Appointment adds cell therapy and corporate development expertise as Kyverna advances KYV-101 in autoimmune disease trials.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mert Aktar

Class III director

KYTX · Kyverna Therapeutics, Inc.

Effective: 2024-10-20
Filed: October 21, 2024, 7:59 PM ET

On October 20, 2024, the board of directors (the "Board") of Kyverna Therapeutics, Inc. (the "Company") appointed Mert Aktar as a Class III director of the Company, effective October 20, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mert Aktar was appointed as Class III director at Kyverna Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On October 20, 2024, the board of directors (the "Board") of Kyverna Therapeutics, Inc. (the "Company") appointed Mert Aktar as a Class III director of the Company, effective October 20, 2024.

View on SEC.gov

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-089095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.